ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
FASgen Announces A New Discovery In Obesity Research
FASgen is pleased to report the
publication of important new research results in the obesity field using
FAS89B, one of the Company's proprietary compounds. FASgen is a leader in
the field of research into selective inhibition of fatty acid synthase
(FASi), and has conducted extensive research in the area of metabolic
disease disorders, specifically for the treatment of obesity and fatty
liver disease. The Company has a long-standing cooperation with The Johns
Hopkins University, and that joint research has produced the new
discoveries in the regulation of weight loss by the stimulation of
carnitinepalmitoyl-transferase-1 (CPT-1). FAS89B was characterized in vitro
as a selective inhibitor of brain CPT-1 and produced in vivo results in
mice of decreased feeding for three days and persistent weight loss of six
days, with no evidence of conditioned taste aversion. See, "Pharmacological
Stimulation of Brain Carnitine-Transerase-1 Decreases Food Intake and Body
Weight," Ronnett, et al, Am J Physiol Regul Integr Physiol (December 8,
2007). This new discovery adds another tool for FASgen to use, in addition
to FASi and GPATi compounds already in research, in its ongoing program of
research into the field of treatment for obesity and fatty liver disease.
About FASgen, Inc.: FASgen, Inc. is a drug development company founded
in 2000 by four distinguished Johns Hopkins researchers to create new
therapeutic products based on the selective inhibition of fatty acid
biosynthesis. The Company has the exclusive license from Johns Hopkins to
more than 15 years of research in the field, which research continues under
a sponsored research agreement with the University.
The Company has designed and synthesized many compounds that
selectively inhibit fatty acid biosynthesis. One group of these compounds
holds great promise for new highly specific therapeutics for cancer;
additional compounds have the potential of specific therapeutics for
obesity and related metabolic disorders; and, an additional group of
compounds have the potential of specific therapeutics for TB, including
multiple drug resistant TB (MDR-TB) and latent TB infections that affect
one third of the world's population. For more information, visit FASgen's
website at http://www.fasgen.com.
FASgen, Inc.
http://www.fasgen.com
Anunta o FASgen nouã Discovery În Obezitate de cercetare - FASgen Announces A New Discovery In Obesity Research - articole medicale engleza - startsanatate
